Coverage
-
March 24, 2022
Arthrex will argue next week that the Federal Circuit must undo the Patent Trial and Appeal Board's invalidation of its suture patent because the patent office’s interim leader lacks the power to review that ruling under a U.S. Supreme Court decision involving the company. Here's a look at where that case stands — plus all the other major intellectual property matters on deck in the coming week.
1 other articles on this case.
View all »